"Vinblastine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
| Descriptor ID |
D014747
|
| MeSH Number(s) |
D03.132.436.681.827.650 D03.633.100.473.402.681.827.650
|
| Concept/Terms |
Velban- Velban
- Vinblastina Lilly
- Velbe
|
Below are MeSH descriptors whose meaning is more general than "Vinblastine".
Below are MeSH descriptors whose meaning is more specific than "Vinblastine".
This graph shows the total number of publications written about "Vinblastine" by people in this website by year, and whether "Vinblastine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 7 | 8 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 4 | 5 |
| 1997 | 0 | 5 | 5 |
| 1998 | 4 | 4 | 8 |
| 1999 | 1 | 5 | 6 |
| 2000 | 5 | 4 | 9 |
| 2001 | 4 | 3 | 7 |
| 2002 | 4 | 10 | 14 |
| 2003 | 3 | 5 | 8 |
| 2004 | 2 | 4 | 6 |
| 2005 | 1 | 5 | 6 |
| 2006 | 1 | 7 | 8 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 6 | 6 |
| 2010 | 2 | 9 | 11 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 5 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 0 | 10 | 10 |
| 2015 | 1 | 4 | 5 |
| 2016 | 0 | 7 | 7 |
| 2017 | 0 | 9 | 9 |
| 2018 | 0 | 6 | 6 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vinblastine" by people in Profiles.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17; 391(15):1379-1389.
-
Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatr Blood Cancer. 2024 Aug; 71(8):e31091.
-
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 10; 19(10):860-870.
-
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 05; 64(5):1017-1025.
-
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):527-534.
-
Older patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094.
-
Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. Pediatr Blood Cancer. 2022 05; 69(5):e29601.
-
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):e435-e442.
-
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021 Jun; 8(6):e410-e421.
-
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.